Phase 3 COVID-19 Trial on Track for Independent Safety, Efficacy Review
Source: Streetwise Reports  (12/29/20)
Revive Therapeutics plans to apply for emergency use authorization of its drug Bucillamine as a treatment for the indication. More >

Myovant Shares Rise 25% on $4.2 Billion Development Partnership with Pfizer
Source: Streetwise Reports  (12/28/20)
Shares of Myovant Sciences established a new 52-week high after the company entered into an agreement with Pfizer to jointly develop and commercialize ORGOVYXâ„¢ (relugolix) for advanced prostate cancer and relugolix combination tablet for women's health in the U.S. and Canada. More >

Analyst: Differences Between Two Possible COVID-19 Therapies Noteworthy
Source: Streetwise Reports  (12/23/20)
The factors that set Athersys' stem cell product MultiStem apart from a competitor's therapeutic are provided in a Dawson James Securities report. More >

Positive Data from Phase 3 Adult ADHD Trial Lifts Supernus Pharma Shares 17% Higher
Source: Streetwise Reports  (12/23/20)
Supernus Pharmaceuticals shares reached a new 52-week high price after the company reported positive results from its Phase 3 Study of SPN-812 for treating adults with attention deficit hyperactivity disorder. More >

Life Sciences Company to Acquire Psychedelic Pharmaceutical Firm's Psilocybin Program
Source: Streetwise Reports  (12/22/20)
Revive Therapeutics reported it has submitted a non-binding letter of intent to acquire 100% of PharmaTher Inc.'s psilocybin program. More >

Pharma Developer Provides Interim Update from Phase 2b Ifenprodil COVID-19 Study
Source: Streetwise Reports  (12/21/20)
Algernon Pharmaceuticals provided additional interim data from its Phase 2b/3 Ifenprodil COVID-19 study outlining several potential primary endpoints for the Phase 3 portion of the trial. More >

Agios Pharma Agrees to Sell Oncology Business to Servier for US$2 Billion Plus Royalties
Source: Streetwise Reports  (12/21/20)
Shares of Agios Pharmaceuticals traded 30% higher after the company reported that it has agreed to sell its oncology research business to France's Servier Group in a transaction valued up to US$2 billion in cash plus future royalties. More >

Life Sciences Firm Reports Year of Record Breaking Orders
Source: Streetwise Reports  (12/18/20)
Avivagen Inc. reported FY/20 audited financial results that included a 20.5% increase in YoY revenue. More >

BioTelemetry Shares Beat Higher on Royal Philips $2.8 Billion Buyout Offer
Source: Streetwise Reports  (12/18/20)
Shares of BioTelemetry Inc. rise 16.5% to a new 52-week high after Royal Philips agreed to acquire the company for US$2.8 billion, or US$72.00 per share in an all cash transaction. More >

Humanigen Shares Rise on Completing Phase 1 Brain Cancer Trial Enrollment
Source: Streetwise Reports  (12/17/20)
Shares of Humanigen Inc. traded 24% higher after the company reported that it had successfully completed enrollment of patients in a Phase 1 Study of ifabotuzumab in glioblastoma multiforme. More >

Why XPhyto's PCR Test Kit Is a Game Changer for COVID-19 Testing
Source: Knox Henderson for Streetwise Reports  (12/17/20)
Extraordinary achievement promises to help turn the tide against the COVID 19 pandemic, Knox Henderson writes. More >

US Specialty Pharma Makes 'Another Acquisition to Bolster Topline'
Source: Streetwise Reports  (12/16/20)
The transaction details and expected impact on Aytu BioScience's balance sheet are provided in a Ladenburg Thalmann report. More >

Analyst: Small Cap's Interim COVID-19 Trial Data Show 'Two Positive Early Trends'
Source: Streetwise Reports  (12/16/20)
Partial Phase 2b results of this evaluation of Algernon Pharmaceuticals' antagonist are provided in a Mackie Research Capital Corp. report. More >

Pharma Developer Reports Interim Data Is Trending Positively in Phase 2b/3 COVID-19 Trial
Source: Streetwise Reports  (12/16/20)
Algernon Pharmaceuticals reported that interim data from its Phase 2b/3 Ifenprodil COVID-19 study is showing very positive signs of reducing the need for mechanical ventilators. More >

Eli Lilly's $1.04 Billion Buyout Offer Sends Prevail Therapeutics' Shares 82% Higher
Source: Streetwise Reports  (12/15/20)
Shares of Prevail Therapeutics reached a new 52-week high after the company reported it has signed a definitive agreement to be acquired by Ely Lilly in a deal valued up to $1.04 billion. More >

Alexion Pharma Shares Jump 30% on AstraZeneca's $39 Billion Buyout Offer
Source: Streetwise Reports  (12/14/20)
Shares of Alexion Pharmaceuticals reached a new 52-week high after the company reported it entered into a definitive agreement to be acquired by AstraZeneca in a combination cash and stock deal valued at US$39 billion. More >

NantHealth's Shares Gain 35% after Presenting Breast Cancer Treatment Insights to Texas Conference
Source: Streetwise Reports  (12/11/20)
Shares of NantHealth Inc. climbed to a new 52-week high after the healthcare IT company presented what it called significant treatment insights at the 2020 San Antonio Breast Cancer Symposium. More >

TG Therapeutics Shares Rise 40% on Positive Topline Data from Two Phase 3 RMS Trials
Source: Streetwise Reports  (12/10/20)
Shares of TG Therapeutics reached a new 52-week high after the company released positive topline results from the Phase 3 ULTIMATE I & II Studies of ublituximab as a monotherapy for treating relapsing multiple sclerosis. More >

Grenwich Shares Skyrocket 2,300% After Firm Presents 5-Year Clinical Breast Cancer Trial Data Showing 0% Recurrence
Source: Streetwise Reports  (12/9/20)
Shares of Grenwich Lifesciences soared more than 2,300% to a new 52-week high after the company gave a poster presentation of 5-year data for the Phase 2b GP2 clinical trial that showed 0% recurrence of breast cancer. More >

Curis Shares Soar 300% on Positive Data from Two Ongoing Phase 1 Cancer Studies
Source: Streetwise Reports  (12/8/20)
Curis Inc. shares reached a new 52-week high after the cancer therapeutics developer reported positive preliminary data from two Phase 1 studies, one treating relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes and another treating relapsed or refractory non-Hodgkin's lymphoma. More >

Fate Therapeutics Shares Twist 37% Upward on Data from Two Phase 1 B-cell Lymphoma Trials
Source: Streetwise Reports  (12/7/20)
Fate Therapeutics shares set a new 52-week high after the firm reported positive interim data from its Phase 1 Study of FT516 in combination with rituximab for B-cell lymphoma. In a separate Phase 1 study, the company presented the results of a patient treated with natural killer cell cancer immunotherapy FT596 in refractory diffuse large B-cell lymphoma. More >

Biotech's Potentially Disruptive Diagnostics Platform on 'Cusp of Commercialization'
Source: Streetwise Reports  (12/6/20)
Recent trial results, a timeline to the launch of Quotient's system and the reasons the debut should be successful are discussed in a Cowen report. More >

BioCryst Awarded FDA Approval for Medicine Preventing Attacks in HAE Patients
Source: Streetwise Reports  (12/4/20)
BioCryst Pharmaceuticals shares traded 17% higher after the company reported that the FDA approved its once-daily oral therapy ORLADEYOâ„¢ (berotralstat) for prevention of attacks in hereditary angioedema patients. More >

Oramed Pharma Shares Gain 11% as Firm Initiates Phase 2 NASH Trial of Oral Insulin
Source: Streetwise Reports  (12/3/20)
Shares of Oramed Pharmaceuticals traded higher after the company announced that it has initiated a Phase 2 NASH trial of oral insulin as a complementary agent or alternative to insulin injections. More >

Biotech Licenses Platform for Faster Pathway for Cancer and COVID-19 Vaccine Trials
Source: Streetwise Reports  (12/2/20)
The rationale behind OncoSec Medical using this system is discussed in a Dawson James report. More >